343
Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.
 clinical hazards: Effect; Delavirdine and efavirenz (but not nevirapine): Treatment; Delavirdine: Treatment.Drug; efavirenz: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 clinical hazards: Effect; Delavirdine and efavirenz (but not nevirapine): Treatment; Delavirdine: Treatment.Drug; efavirenz: Treatment.Drug